Drug Detail

Information about CPI-613

Generic Name
IND	CPI-613
Brand Name (US)
Manufacturer	Cornerstone Pharmaceuticals
Drug Type	Small molecule
Delivery	Intravenous
Approval Status	Phase 2
Indications
Overall Strategy	GIST Tumor Based
Strategy	Krebs cycle modulation
Drug Category	SDH-directed

CPI-613 is the lead candidate from Cornerstone Pharma. that, through a novel mechanism of action, targets metabolic changes considered to be common to many, if not all, cancer types. CPI-613 is currently being evaluated in several ongoing Phase I/II trials.
The proposed mechanisms of action includes inhibition of proteins within the mitocondria, specifically α-ketoglutarate dehydrogenase (KGDH) and pyruvate dehydrogenase (PDH). It is unclear if it directly or indirectly inhibits these two proteins.